Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

NCT00577577 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Myotonic Dystrophy Type 1

Interventions

DRUG: rhIGF-I/rhIGFBP-3
DRUG: placebo

Sponsor

Insmed Incorporated

Collaborators

[object Object]